The Russian drug “Longidaza” received a patent in the territory of the Republic of India

The Russian pharmaceutical company Petrovax received a patent in India for the original drug Longidaza, protecting its exclusive right in the country for 20 years. Thus, the company noted, Longidaza enters the markets of the BRICS countries, continuing to win international recognition.

Longidaza is an original Russian enzyme preparation that has been widely used in Russia and neighboring countries for more than 15 years in various nosologies: pulmonology, urology, cosmetology and other fields of medicine. During the pandemic, doctors use Longidaza for the prevention and treatment of complications caused by coronavirus infection, for post-COVID rehabilitation.

Entering the Indian market is another step that continues the expansion of the geographical expansion of the drug. In 2015, the WHO (World Health Organization) recognized the originality of the Longidase drug molecule by assigning it the international non-proprietary name (INN) bovhyaluronidase azoximer (bovhyaluronidase azoximer). In 2021, the drug received a European patent, which is valid in the UK, Germany, France, Switzerland, Ireland and Belgium. In 2021, sales of the drug in Russia and abroad exceeded 1.7 million units, of which the share of export deliveries of the drug was 9%.

Petrovax explained that the market of the BRICS countries has great potential for the use of drugs from the Longidaza group. Only in India, according to preliminary estimates, there are about 130 thousand patients diagnosed with idiopathic pulmonary fibrosis. According to other data, in large countries such as Brazil, Russia, India and China (the BRICS region), this figure may total about 2 million people.

There are contraindications to the use and use of the drug, you must read the instructions for use or get expert advice.